Strides Pharma Science Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹1,323Cr
- +11.2% YoY
- +10.7% QoQ
- Net profit
- ₹129Cr
- +50% YoY
- −38% QoQ
- Margin
- 18%
- 0 pp YoY
- −2 pp QoQ
Guidance rank: #76 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q4 FY26 call signalled
1 of 3 strong
The short version
U.S. Strides expects sequential quarter-on-quarter growth, continuing the trend seen in FY26 Q4 with 11% growth (14% excluding institutional business).
From Strides Pharma Science Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- U.S. business growth expected to accelerate from H2 FY27 onwards with new product launches, including nasal sprays and controlled substances.
- Targeted U.S. revenue aspiration of $375 million to $400 million by FY28, representing about 15%-20% CAGR from current base.
- Controlled substances business is a new growth engine; additional quota allocations pending with DEA may drive future growth.
- Nasal sprays and complex generics (transdermals, films) expected to contribute meaningfully from FY28 and FY29 onwards.
- Ex-U.S. markets showing strong, consistent growth with 21% CAGR in FY26 and growing faster than the U.S. market.
2 more points from Strides Pharma Science Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Strides Pharma Science Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total capital investments in FY26 were INR418 crores, including:
- INR236 crores tangible capex focused on:
- Nasal spray capabilities development
- Enhancing capacities for Ex-U.S. business
- Acquisition of new office space in the U.K.
- INR182 crores intangible investments covering:
- Acquisition of global product rights to drive growth in U.S. and Ex-U.S. markets
- Significant upgrade to global ERP platform migrating to SAP HANA
- Future capex run rate expected around INR300 crores annually over next 2 years:
- Tangible capex largely maintenance capex after recent growth investments
- Intangible investments expected to continue for acquiring global rights and fast-tracking growth
2 more points from Strides Pharma Science Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Strides Pharma Science Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Strides Pharma Science Ltd said on order book & pipeline — free account, 30 seconds.
Strides Pharma Science Ltd — Quarterly revenue & net profit
Strides Pharma Science Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,323 | 1,190 | +11.2% | 1,195 | +10.7% |
| Operating profit (EBITDA) | 240 | 218 | +10.1% | 236 | +1.7% |
| Operating margin | 18% | 18% | 0 pp | 20% | -2 pp |
| Profit before tax | 148 | 106 | +39.6% | 245 | -39.6% |
| Net profit (PAT) | 129 | 86 | +50% | 208 | -38% |
| EPS (₹) | 13.77 | 8.91 | +54.5% | 21.93 | -37.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.4K Cr, net profit ₹134 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Strides Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Strides Pharma Science Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Strides Pharma Science Ltd Q4 FY26 results?
U.S. Strides expects sequential quarter-on-quarter growth, continuing the trend seen in FY26 Q4 with 11% growth (14% excluding institutional business).
What is Strides Pharma Science Ltd share price analysis?
Strides Pharma Science Ltd currently shows a below-average growth signal. The stock trades at a P/E of 15.4 with a market cap of ₹8,944 Cr. Investors should review the full earnings analysis for detailed insights.
Is Strides Pharma Science Ltd planning capital expenditure?
Total capital investments in FY26 were INR418 crores, including: - INR236 crores tangible capex focused on: - Nasal spray capabilities development - Enhancing capacities for Ex-U.S.
Keep Strides Pharma Science Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
